192 related articles for article (PubMed ID: 7553688)
1. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients.
Adluri S; Helling F; Ogata S; Zhang S; Itzkowitz SH; Lloyd KO; Livingston PO
Cancer Immunol Immunother; 1995 Sep; 41(3):185-92. PubMed ID: 7553688
[TBL] [Abstract][Full Text] [Related]
2. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.
MacLean GD; Reddish MA; Koganty RR; Longenecker BM
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):59-68. PubMed ID: 8859725
[TBL] [Abstract][Full Text] [Related]
3. Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis.
Longenecker BM; Reddish M; Koganty R; MacLean GD
Adv Exp Med Biol; 1994; 353():105-24. PubMed ID: 7527178
[TBL] [Abstract][Full Text] [Related]
4. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells.
Ragupathi G; Howard L; Cappello S; Koganty RR; Qiu D; Longenecker BM; Reddish MA; Lloyd KO; Livingston PO
Cancer Immunol Immunother; 1999 Apr; 48(1):1-8. PubMed ID: 10235483
[TBL] [Abstract][Full Text] [Related]
5. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant.
Longenecker BM; Reddish M; Koganty R; MacLean GD
Ann N Y Acad Sci; 1993 Aug; 690():276-91. PubMed ID: 7690215
[TBL] [Abstract][Full Text] [Related]
6. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn.
O'Boyle KP; Zamore R; Adluri S; Cohen A; Kemeny N; Welt S; Lloyd KO; Oettgen HF; Old LJ; Livingston PO
Cancer Res; 1992 Oct; 52(20):5663-7. PubMed ID: 1394190
[TBL] [Abstract][Full Text] [Related]
7. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
[TBL] [Abstract][Full Text] [Related]
8. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
[TBL] [Abstract][Full Text] [Related]
9. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen.
MacLean GD; Bowen-Yacyshyn MB; Samuel J; Meikle A; Stuart G; Nation J; Poppema S; Jerry M; Koganty R; Wong T
J Immunother (1991); 1992 May; 11(4):292-305. PubMed ID: 1599915
[TBL] [Abstract][Full Text] [Related]
10. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen.
Zhang S; Walberg LA; Ogata S; Itzkowitz SH; Koganty RR; Reddish M; Gandhi SS; Longenecker BM; Lloyd KO; Livingston PO
Cancer Res; 1995 Aug; 55(15):3364-8. PubMed ID: 7614472
[TBL] [Abstract][Full Text] [Related]
11. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant.
MacLean GD; Reddish M; Koganty RR; Wong T; Gandhi S; Smolenski M; Samuel J; Nabholtz JM; Longenecker BM
Cancer Immunol Immunother; 1993; 36(4):215-22. PubMed ID: 8439984
[TBL] [Abstract][Full Text] [Related]
12. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer.
Miles DW; Towlson KE; Graham R; Reddish M; Longenecker BM; Taylor-Papadimitriou J; Rubens RD
Br J Cancer; 1996 Oct; 74(8):1292-6. PubMed ID: 8883420
[TBL] [Abstract][Full Text] [Related]
13. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.
Miles D; Roché H; Martin M; Perren TJ; Cameron DA; Glaspy J; Dodwell D; Parker J; Mayordomo J; Tres A; Murray JL; Ibrahim NK;
Oncologist; 2011; 16(8):1092-100. PubMed ID: 21572124
[TBL] [Abstract][Full Text] [Related]
14. Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2-->6) T antigens.
O'Boyle KP; Markowitz AL; Khorshidi M; Lalezari P; Longenecker BM; Lloyd KO; Welt S; Wright KE
Hybridoma; 1996 Dec; 15(6):401-8. PubMed ID: 8985750
[TBL] [Abstract][Full Text] [Related]
15. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies.
Livingston P; Zhang S; Adluri S; Yao TJ; Graeber L; Ragupathi G; Helling F; Fleisher M
Cancer Immunol Immunother; 1997 Jan; 43(6):324-30. PubMed ID: 9067403
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine.
Ragupathi G; Damani P; Srivastava G; Srivastava O; Sucheck SJ; Ichikawa Y; Livingston PO
Cancer Immunol Immunother; 2009 Sep; 58(9):1397-405. PubMed ID: 19190907
[TBL] [Abstract][Full Text] [Related]
17. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
[TBL] [Abstract][Full Text] [Related]
18. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy.
Reddish MA; MacLean GD; Poppema S; Berg A; Longenecker BM
Cancer Immunol Immunother; 1996 Jun; 42(5):303-9. PubMed ID: 8706053
[TBL] [Abstract][Full Text] [Related]
19. Clinical development of the STn-KLH vaccine (Theratope).
Ibrahim NK; Murray JL
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S139-43. PubMed ID: 12620151
[TBL] [Abstract][Full Text] [Related]
20. Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies.
Ragupathi G; Deshpande PP; Coltart DM; Kim HM; Williams LJ; Danishefsky SJ; Livingston PO
Int J Cancer; 2002 May; 99(2):207-12. PubMed ID: 11979435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]